Neuberger Berman Group’s Cidara Therapeutics CDTX Stock Holding History

Neuberger Berman Group’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-184,873	Closed	-$40.8M	–	2175
2025 Q4	$40.8M	Buy	+184,873	New	+$29.9M	0.03%	506

Neuberger Berman Group's CDTX Position: Q1 2026 in Review

Neuberger Berman Group sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 184,873 shares — an estimated $40.8M sold.

Neuberger Berman Group first reported a position in CDTX in Q4 2025 and held it in 1 quarter. The position peaked at $40.8M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Neuberger Berman Group reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Neuberger Berman Group sold 184,873 Cidara Therapeutics shares in Q1 2026, an estimated $40.8M.
Neuberger Berman Group first reported a position in Cidara Therapeutics in Q4 2025 and held it in 1 quarter.
Neuberger Berman Group's Cidara Therapeutics position peaked at $40.8M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.